Immunotherapy combo shows promise in rectal cancer after standard treatment

NCT ID NCT05009069

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding two immunotherapy drugs (atezolizumab and tiragolumab) after standard chemoradiation can help eliminate tumors in people with locally advanced rectal cancer. About 58 participants will receive either the drug combination or atezolizumab alone before surgery. The main goal is to see if the cancer completely disappears by the time of surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER RECTAL NEOPLASMS

Contacts and locations

Show contact details

Locations

Beijing Cancer Hospital

Beijing, 100142, China
First Hospital of China Medical University

Shenyang, 110001, China
The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, 310009, China
The Sixth Affiliated Hospital of Sun Yat-sen University

Guangzhou, 510655, China
Zhongshan Hospital Fudan University

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.